These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 3397034)

  • 1. Improvement of immunologic abnormalities associated with hyperthyroidism of Graves' disease during methimazole treatment.
    Murakami M; Koizumi Y; Aizawa T; Yamada T; Ishihara M; Hasegawa Y; Ogata H; Kamoi K; Kaneko K
    Horm Metab Res; 1988 Apr; 20(4):235-8. PubMed ID: 3397034
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Studies of thyroid function and immune parameters in patients with hyperthyroid Graves' disease in remission.
    Murakami M; Koizumi Y; Aizawa T; Yamada T; Takahashi Y; Watanabe T; Kamoi K
    J Clin Endocrinol Metab; 1988 Jan; 66(1):103-8. PubMed ID: 3121661
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Administration of thyroxine in treated Graves' disease. Effects on the level of antibodies to thyroid-stimulating hormone receptors and on the risk of recurrence of hyperthyroidism.
    Hashizume K; Ichikawa K; Sakurai A; Suzuki S; Takeda T; Kobayashi M; Miyamoto T; Arai M; Nagasawa T
    N Engl J Med; 1991 Apr; 324(14):947-53. PubMed ID: 1900575
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of single daily dose of methimazole and propylthiouracil in the treatment of Graves' hyperthyroidism.
    He CT; Hsieh AT; Pei D; Hung YJ; Wu LY; Yang TC; Lian WC; Huang WS; Kuo SW
    Clin Endocrinol (Oxf); 2004 Jun; 60(6):676-81. PubMed ID: 15163329
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of Graves' disease: effects of the administration of L-thyroxine associated with methimazole as a single daily dose.
    Perozim LM; Lima N; Knobel M; Cavaliere H; Medeiros-Neto G
    Eur J Med; 1993 Feb; 2(2):70-4. PubMed ID: 8258020
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reappraisal of the 3,5,3'-triiodothyronine-suppression test in the prediction of long term outcome of antithyroid drug therapy in patients with hyperthyroid Graves' disease.
    Yamada T; Koizumi Y; Sato A; Hashizume K; Aizawa T; Takasu N; Nagata H
    J Clin Endocrinol Metab; 1984 Apr; 58(4):676-80. PubMed ID: 6421866
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma atrial natriuretic peptide, plasma renin activity and aldosterone during treatment of hyperthyroidism due to Graves' disease.
    Shigematsu S; Iwasaki T; Aizawa T; Ishihara M; Shinoda T; Yamada T; Sato A; Takemura Y
    Horm Metab Res; 1989 Sep; 21(9):514-8. PubMed ID: 2531114
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An elevation of serum immunoglobulin E provides a new aspect of hyperthyroid Graves' disease.
    Yamada T; Sato A; Komiya I; Nishimori T; Ito Y; Terao A; Eto S; Tanaka Y
    J Clin Endocrinol Metab; 2000 Aug; 85(8):2775-8. PubMed ID: 10946880
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Graves' disease: evolution and prognosis after eight months of treatment with methimazole.
    Gauna AT; Guillén CE; Sartorio GC; Soto RJ
    Medicina (B Aires); 1992; 52(3):207-12. PubMed ID: 1364158
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Remission of Graves' hyperthyroidism treated with methimazole.
    Bolaños F; González-Ortiz M; Durón H; Sánchez C
    Rev Invest Clin; 2002; 54(4):307-10. PubMed ID: 12415954
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro suppression of anti-TSH receptor antibody by autologous anti-idiotypic antibody in patients with Graves' disease.
    Balázs C; Molnár I
    Acta Microbiol Immunol Hung; 1995; 42(2):163-9. PubMed ID: 7551709
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum thyroglobulin concentration as an indicator for assessing thyroid stimulation in patients with Graves' disease during antithyroid drug therapy.
    Aizawa T; Ishihara M; Koizumi Y; Hashizume K; Takasu N; Yamada T; Kobayashi I; Watanabe T; Shimizu Z
    Am J Med; 1990 Aug; 89(2):175-80. PubMed ID: 2166430
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Time-dependent effect of cyclosporin-A on the TSH-receptor antibody synthesis in patients with Graves' disease.
    Balázs C; Kiss E; Farid NR
    Acta Med Hung; 1988; 45(1):43-52. PubMed ID: 3412862
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Presence of antideoxyribonucleic acid antibody in patients with hyperthyroidism of Graves' disease.
    Katakura M; Yamada T; Aizawa T; Hiramatsu K; Yukimura Y; Ishihara M; Takasu N; Maruyama K; Kameko M; Kanai M
    J Clin Endocrinol Metab; 1987 Mar; 64(3):405-8. PubMed ID: 3493254
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of combination therapy with propylthiouracil and cholestyramine in the treatment of Graves' hyperthyroidism.
    Tsai WC; Pei D; Wang TF; Wu DA; Li JC; Wei CL; Lee CH; Chen SP; Kuo SW
    Clin Endocrinol (Oxf); 2005 May; 62(5):521-4. PubMed ID: 15853819
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pituitary-thyroid feedback regulation in patients with Graves' disease during antithyroid drug therapy.
    Yamada T; Takasu N; Sato A; Aizawa T; Koizumi Y
    J Clin Endocrinol Metab; 1982 Jan; 54(1):83-8. PubMed ID: 6798061
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The significance of antithyroglobulin and antithyroidal microsomal antibodies in patients with hyperthyroidism due to Graves' disease treated with antithyroidal drugs.
    Takaichi Y; Tamai H; Honda K; Nagai K; Kuma K; Nakagawa T
    J Clin Endocrinol Metab; 1989 Jun; 68(6):1097-100. PubMed ID: 2470772
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effective methimazole dose for childhood Graves' disease and use of free triiodothyronine combined with concurrent thyroid-stimulating hormone level to identify mild hyperthyroidism and delayed pituitary recovery.
    Slyper AH; Wyatt D; Boudreau C
    J Pediatr Endocrinol Metab; 2005 Jun; 18(6):597-602. PubMed ID: 16042328
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fetal Goitrous Hyperthyroidism in a Pregnant Woman with Triiodothyronine-Predominant Graves' Disease.
    Washio K; Uenaka M; Tanimura K; Deguchi M; Nishida K; Fujioka K; Yamada H
    Kobe J Med Sci; 2021 Feb; 66(4):E153-E158. PubMed ID: 33994519
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patients with Graves' disease who developed insulin autoimmune syndrome (Hirata disease) possess HLA-Bw62/Cw4/DR4 carrying DRB1*0406.
    Uchigata Y; Kuwata S; Tsushima T; Tokunaga K; Miyamoto M; Tsuchikawa K; Hirata Y; Juji T; Omori Y
    J Clin Endocrinol Metab; 1993 Jul; 77(1):249-54. PubMed ID: 8325948
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.